



PRESS RELEASE

AFFLUENT MEDICAL POSTPONES PLANNED INITIAL PUBLIC OFFERING (IPO) ON THE EURONEXT GROWTH® MARKET IN PARIS

Paris, France, June 21, 2018 – Affluent Medical, a new French *medtech* player, today announces the postponement of its initial public offering (IPO) to list its shares for trading on the Euronext Growth market in Paris.

Due to difficult market conditions, and ongoing strategic discussions being under way with potential partners, Affluent Medical has decided to postpone its IPO project. As a result, Affluent Medical indicates that all subscription orders placed on the date of this press release are automatically canceled.

Daniele Zanotti, CEO of Affluent Medical, comments:

“The current financial markets conditions do not offer favorable conditions to carry out the IPO of Affluent Medical, so we have decided to differ our offering in the interests of the company, its shareholders and its employees. Nevertheless, the Affluent Medical team remains focused and committed to continue the development of its new generation of minimally invasive treatments. In addition, discussions are underway for a strategic agreement with potential partners. However, the IPO of Affluent Medical remains an option that will be revisited in due time”.

Affluent Medical is a *medtech* specialized in the areas of heart diseases, vascular diseases and urinary incontinence which develops 4 new generation implants that can reproduce the physiological functions of defective organs. These devices, favoring a minimally invasive approach, will significantly improve the lives of patients as well as the action of caregivers. They all meet a medical need that has not been met so far.

About AFFLUENT MEDICAL

Affluent Medical is a new French *medtech* player with the ambition to become one of the European leaders in the treatment of heart and vascular diseases - which are the leading cause of death throughout the world - and of urinary incontinence today affecting one in four adults, subject to the achievement of complementary steps and obtention of regulatory authorization. Affluent Medical is developing innovative, next-generation *best-in-class* minimally invasive implants to restore key physiological functions in these areas. The company's four medical devices are currently in preclinical and clinical validation phases, and a first medical device is expected to be launched by 2020. Affluent Medical was incorporated in February 2018, from the combination of four technologies drawn from Truffle Capital's portfolio: KARDIOZIS, KALIOS, EPGON and ARTUS.

For more information: www.affluentmedical.com



Contacts

Affluent Medical

Henri Lefebvre,
CFO
investor@affluentmedical.com
Tél. : + 33 (0) 1 82 28 46 00

Communication financière

ACTIFIN
Julien Mouret
affluentmedical@actifin.fr
Tél.: + 33 (0) 1 56 88 11 14

Relations Presse

ALIZE RP
Caroline Carmagnol / Wendy Rigal
/Tatiana Vieira
affluentmedical@alizerp.com
Tél. : + 33 (0) 1 44 54 36 66

Disclaimer

This press release and the information it contains do not constitute an offer to sell or to subscribe, or a solicitation to purchase or subscribe shares in Affluent Medical.

The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations. This press release is a promotional message and not a prospectus in the meaning of Directive 2003/71/EC of the European Parliament and Council dated 4 November 2003, as amended (the "Prospectus Directive").

This press release does not constitute or form part of an offer of securities or a solicitation for purchase, subscription or sale of securities in the United States. Securities may not be offered, subscribed or sold in the United States without registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and other applicable state securities law, except pursuant to an exemption from registration. Affluent Medical shares have not been and will not be registered under the U.S. Securities Act, and Affluent Medical does not intend to undertake a public offering of its securities in the United States.

With respect to the member states of the European Economic Area other than France (the "Member States") having implemented the Prospectus Directive into law, no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in one of such Member States. As a result, the securities of Affluent Medical may not and will not be offered in any Member State other than France, except in accordance with the exemptions set forth in Article 3 of the Prospectus Directive, if they have been implemented in the relevant member states or in the other case which does not require the publication by Affluent Medical of a prospectus pursuant to the Prospectus Directive and/or applicable regulation in the member states.

This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (1) who are not in the United Kingdom; (2) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"); or (3) who are « high net worth entities », and other persons falling within the provisions of Article 49 (2) (a) to (d) of the Order (those persons cited in (1), (2) and (3) together being designated as "Relevant Persons").

This press release is aimed solely at Relevant Persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons, and may only be made by Relevant Persons.

Not for release, publication or distribution, directly or indirectly, in the United States, Australia, Canada or Japan.